Provided by Tiger Trade Technology Pte. Ltd.

Bio-Path Holdings, Inc.

0.0580
-0.0080-12.12%
Volume:3.11K
Turnover:181.42
Market Cap:536.04K
PE:-0.01
High:0.0644
Open:0.0570
Low:0.0570
Close:0.0660
52wk High:0.7899
52wk Low:0.0501
Shares:9.24M
Float Shares:8.85M
Volume Ratio:0.40
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1250
EPS(LYR):-33.6360
ROE:-3325.71%
ROA:-373.32%
PB:-0.07
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Bio-Path Holdings, Inc.
Exchange:
PINK LIMITED
Establishment Date:
2007
Employees:
10
Office Location:
4710 Bellaire Boulevard,Suite 210,Bellaire,Texas,United States
Zip Code:
77401
Fax:
- -
Introduction:
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.